Is Trident Lifeline overvalued or undervalued?

As of 26 September 2025, Trident Lifeline's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 21.47, an EV to EBITDA ratio of 16.28, and a Price to Book Value of 6.88. These ratios suggest that the stock is trading at a premium compared to its earnings and asset values.
In comparison to its peers, Trident Lifeline's valuation stands out as notably high, especially when juxtaposed with Sun Pharma, which has a PE ratio of 33.18, and Cipla, with a PE ratio of 22.45. While Trident's PEG ratio of 0.26 appears attractive, the overall valuation metrics indicate that it is not justified given the current market conditions. Additionally, despite a recent positive performance with a 1-week return of 2.24% compared to a -2.66% return for the Sensex, the long-term outlook remains concerning, especially with a 1-year return of -7.11%.